Scholar Rock finally won FDA approval. Why did SRRK stock fall 6% when ISEMBYLD launched?
Scholar Rock starts its ISEMBYLD SMA launch after FDA approval, but SRRK falls as investors weigh a roughly $310,000 annual price and execution.
Pharma & Biotech
Pharma & Biotech
Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?
Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.
Pharma & Biotech
Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients
Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.